did reverse split finalize yet ????? re; $VTEQ - Offers the world's first FDA cleared RFID microtransponder technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care.
VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. answer; is this for cancer stuff ?????
There are 2 major takeaways investors should monitor based on this news:
1. The Establishment Labs option essentially values VTEQD's breast implant marker business at $10 Million dollars, with the current market cap around $40k, this would have VeriTeQ severely undervalued by the market.
2. Perhaps even more interesting, is the fact that we have yet to hear about Mentor or Allergen on this matter. These companies together represent 81% of the breast implant market, and currently have no competing technologies in development. Knowing the FDA's new requirements, as well as the cost associated with developing a technology like VeriTeQ's, it would seem logical that VeriTeQ could begin to receive interest from these major players in the implantation market."
On July 8, 2013, VeriTeQ completed a share exchange agreement with Digital Angel Corporation, which trades as DIGA. Digital Angel is changing its name change to VeriTeQ and will also change its stock symbol.
New Mandate Will Help Sell Veriteq's FDA-Approved Microchip
Most companies are trying to sell products, but very few companies have the government mandating purchases in their product category.
Veriteq (OTCQB:VTEQ) found itself in this enviable position just a few months ago and will continue to enjoy this luck for the near-term future.
Because of an FDA ruling with an initial compliance deadline of October 2014, Veriteq will begin to enjoy mandated demand for its niche industry before October 2014 and has forecasted revenue of $239 million - many multiples of its current market capitalization - with 61% gross profit margins.
News 
Market Data 
Discover 
